Cargando…

Survival trends among non‐small‐cell lung cancer patients over a decade: impact of initial therapy at academic centers

BACKGROUND: Treatment of non‐small‐cell lung cancer (NSCLC) has been rapidly advancing over the last decade. Academic centers are considered equipped with better expertise. NSCLC outcome trends in novel therapeutic era and impact of initial treatment at academic centers have not been reported. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lou, Yanyan, Dholaria, Bhagirathbhai, Soyano, Aixa, Hodge, David, Cochuyt, Jordan, Manochakian, Rami, Ko, Stephen J., Thomas, Mathew, Johnson, Margaret M., Patel, Neal M., Miller, Robert C., Adjei, Alex A., Ailawadhi, Sikander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198232/ https://www.ncbi.nlm.nih.gov/pubmed/30175515 http://dx.doi.org/10.1002/cam4.1749

Ejemplares similares

Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies
por: Soyano, Aixa E., et al.
Publicado: (2018)

Survival of Black and White Patients With Stage IV Small Cell Lung Cancer
por: Shi, Huashan, et al.
Publicado: (2021)

Association of Race, Socioeconomic Factors, and Treatment Characteristics With Overall Survival in Patients With Limited-Stage Small Cell Lung Cancer
por: Zhou, Kexun, et al.
Publicado: (2021)

Cancer immunotherapy beyond immune checkpoint inhibitors
por: Marin-Acevedo, Julian A., et al.
Publicado: (2018)

Next generation of immune checkpoint therapy in cancer: new developments and challenges
por: Marin-Acevedo, Julian A., et al.
Publicado: (2018)

Cost Analysis of R-CHOP Versus Dose-Adjusted R-EPOCH in Treatment of Diffuse Large B-Cell Lymphoma with High-Risk Features
por: Dholaria, Bhagirathbhai, et al.
Publicado: (2020)

Emerging therapeutic agents for lung cancer
por: Dholaria, Bhagirathbhai, et al.
Publicado: (2016)

Targeted therapy in advanced non-small cell lung cancer: current advances and future trends
por: Majeed, Umair, et al.
Publicado: (2021)

A Panel Evaluation of the Changes in the General Public’s Social-Media-Following of United States’ Public Health Departments during COVID-19 Pandemic
por: Khokhar, Areej, et al.
Publicado: (2021)

Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia
por: Kumar, Vivek, et al.
Publicado: (2019)

Trends in participant race and sex reporting in lung cancer phase III clinical trials
por: Aslam, Faaiq N., et al.
Publicado: (2023)

Landmark Cancer Clinical Trials and Real-World Patient Populations: Examining Race and Age Reporting
por: Jayakrishnan, Thejus, et al.
Publicado: (2021)

Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades
por: Liu, Weiping, et al.
Publicado: (2020)

Second primary acute lymphoblastic leukemia in adults: a SEER analysis of incidence and outcomes
por: Swaika, Abhisek, et al.
Publicado: (2017)

Patients with high-grade alectinib-induced skin rash: How do we desensitize these patients? A case report and review of literature
por: Seegobin, Karan, et al.
Publicado: (2020)

Increase and Plateauing of Testicular Cancer Incidence in Austria—A Time Trend Analysis of the Past Four Decades
por: Brönimann, Stephan, et al.
Publicado: (2023)

Three decades of demographic trends among academic emergency physicians
por: Cleveland Manchanda, Emily C., et al.
Publicado: (2022)

Overview of approved CAR‐T therapies, ongoing clinical trials, and its impact on clinical practice
por: Sengsayadeth, Salyka, et al.
Publicado: (2021)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
por: Wiest, Nathaniel, et al.
Publicado: (2021)

Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR
por: Seegobin, Karan, et al.
Publicado: (2021)

Neuroendocrine Tumor Involving the Epicardium
por: Soyano, Aixa E., et al.
Publicado: (2017)

Adjunctive Use of Circulating Tumor DNA Testing in Detecting Pancreas Cancer Recurrence
por: Soyano, Aixa E., et al.
Publicado: (2019)

A Case of Full Recovery from Prolonged Cardiac Arrest after Infusion with Paclitaxel and Pembrolizumab
por: Sh Ahmed, Omar, et al.
Publicado: (2022)

Securing the graft during pandemic: are we ready for cryopreservation for all?
por: Dholaria, Bhagirathbhai, et al.
Publicado: (2020)

Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia
por: Marvin-Peek, Jennifer, et al.
Publicado: (2022)

Immunotherapies targeting stimulatory pathways and beyond
por: Marin-Acevedo, Julian A., et al.
Publicado: (2021)

First Report of Management of Sequential Small Cell Transformation and ALK I1171T Mutation as Resistance Mechanisms in a Patient With ALK-EML4 Fused Non–Small Cell Lung Adenocarcinoma With a Novel Combination of Temozolomide and Lorlatinib: A Case Report
por: Majeed, Umair, et al.
Publicado: (2023)

Rifaximin for Pertuzumab-Related GI Toxicities
por: Soyano, Aixa E., et al.
Publicado: (2017)

Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER‐medicare analysis
por: Ailawadhi, Sikander, et al.
Publicado: (2017)

Academic Leadership for the Next Decade
por: Parekh, Bakul Jayant
Publicado: (2020)

Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments
por: Geethakumari, Praveen Ramakrishnan, et al.
Publicado: (2021)

Chimeric antigen receptor‐T cell therapies: The changing landscape
por: Sengsayadeth, Salyka M., et al.
Publicado: (2021)

Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer
por: Li, Shenduo, et al.
Publicado: (2023)

Neoadjuvant Versus Adjuvant Chemotherapy for Resectable Metastatic Colon Cancer in Non-academic and Academic Programs
por: Hao, Zhonglin, et al.
Publicado: (2022)

CAR T cell therapy in solid tumors: A review of current clinical trials
por: Patel, Urvi, et al.
Publicado: (2021)

Updates in the Use of BCL-2-Family Small Molecule Inhibitors for the Treatment of Relapsed/Refractory Multiple Myeloma
por: Parrondo, Ricardo D., et al.
Publicado: (2022)

Real‐world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia
por: Sun, James, et al.
Publicado: (2021)

Role of bridging therapy during chimeric antigen receptor T cell therapy
por: Bhaskar, Shakthi T., et al.
Publicado: (2021)

Genomic landscape of lung adenocarcinomas in different races
por: Shi, Huashan, et al.
Publicado: (2022)

Chimeric antigen receptor T‐cell therapy: Challenges and framework of outpatient administration
por: Gatwood, Katie S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8be4e22ajt3ni0juceqtf3527l